ArticleEnvironmental health perspectives2025
Obtaining and Evaluating Information on the Use, Release, and Health Effects of Two Types of Long-Chain PFAS Used as Alternatives for Legacy Long-Chain Perfluoroalkyl Acids: A Case Study.
Article in Environmental health perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of regulatory actions to establish maximum contaminant levels on per- and polyfluoroalkyl substances in New Jersey public water systems.Environment international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShort-chain per- and polyfluoroalkyl substances (PFAS) that are less bioaccumulative have been introduced as replacements for long-chain perfluoroalkyl acids (PFAAs) with the intent of reducing health risks. In contrast, alternative PFAS with longer chain lengths may be at least as bioaccumulative and toxic as phased-out long-chain PFAAs. Such alternative PFAS were used and released unbeknownst to regulatory authorities or the public, causing environmental contamination of public health concern.
objectiveThe objective was to examine issues encountered in learning about use, release, and toxicity of alternative PFAS and to demonstrate development of human health benchmarks for alternative PFAS from previously unavailable health effects information. DISCUSSION: Environmental contamination with chloroperfluoropolyether carboxylates (ClPFPECAs) near a New Jersey fluoropolymer manufacturing facility was revealed through a joint New Jersey Department of Environmental Protection (NJDEP)-United States Environmental Protection Agency (USEPA) Office of Research and Development study. Previously unavailable information on use, release, and toxicity of ClPFPECAs and another alternative PFAS, perfluoropolyether dicarboxylates, was obtained through an NJDEP legal directive requiring submission of information on such PFAS used in the state. It was learned that the facility discharged large amounts of these alternative PFAS to air and water for many years, both before and after use of long-chain PFAAs ended, and that they are at least as bioaccumulative and toxic in rats as long-chain PFAAs. Additionally, information from exposed workers shows that ClPFPECAs have a human half-life of several years and are associated with numerous health end points. Reference doses and water concentrations protective of chronic drinking water exposure for these alternative PFAS are below those developed by NJDEP for long-chain PFAAs. The use and release of alternative PFAS described herein created concerning human health risks, unknown to regulatory authorities and the public. Such situations in other locations must be identified to allow for regulatory intervention and prevented in the future. https://doi.org/10.1289/EHP15995.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.